Publicité
Publicité

APRE

APRE logo

Aprea Therapeutics, Inc. Common stock

0.94
USD
Sponsorisé
0.00
+0.52%
09 janv., 14:49 UTC -5
Fermé
exchange

Après-marché

0.95

0.00
+0.21%

APRE Rapports sur les bénéfices

Ratio de surprise positive

APRE a dépassé 16 des 24 dernières estimations.

67%

Prochain rapport

Date du prochain rapport
23 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.36
Variation implicite de Q3 25 (Revenue/ EPS)
-100.00%
/
-23.40%
Variation implicite de Q4 24 (Revenue/ EPS)
-100.00%
/
-26.53%

Aprea Therapeutics, Inc. Common stock earnings per share and revenue

On 12 nov. 2025, APRE reported earnings of -0.47 USD per share (EPS) for Q3 25, missing the estimate of -0.34 USD, resulting in a -36.11% surprise. Revenue reached 2.00 mille, compared to an expected --, with a 0.00% difference. The market reacted with a -4.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analystes forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an baisse of -23.40% EPS, and baisse of -100.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Aprea Therapeutics, Inc. Common stock reported EPS of -$0.47, missing estimates by -36.11%, and revenue of $2.00K, 0% as expectations.
The stock price moved down -4.55%, changed from $1.32 before the earnings release to $1.26 the day after.
The next earning report is scheduled for 23 mars 2026.
Based on 5 analystes, Aprea Therapeutics, Inc. Common stock is expected to report EPS of -$0.36 and revenue of -- for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité